Genscript Biotech 관리

관리 기준 확인 1/4

Genscript Biotech CEO는 Weihui Shao, Jul2021 에 임명되었습니다 의 임기는 3.33 년입니다. 총 연간 보상은 $ 2.48M, 14.3% 로 구성됩니다. 14.3% 급여 및 85.7% 보너스(회사 주식 및 옵션 포함). 는 HK$ 7.65M 가치에 해당하는 회사 주식의 0.034% 직접 소유합니다. 7.65M. 경영진과 이사회의 평균 재임 기간은 각각 3.6 년과 1.7 년입니다.

주요 정보

Weihui Shao

최고 경영자

US$2.5m

총 보상

CEO 급여 비율	14.3%
CEO 임기	3.3yrs
CEO 소유권	0.03%
경영진 평균 재임 기간	3.6yrs
이사회 평균 재임 기간	1.7yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Weihui Shao 의 보수는 Genscript Biotech 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Jun 30 2024	n/a	n/a	-US$177m
Mar 31 2024	n/a	n/a	-US$136m
Dec 31 2023	US$2m	US$353k	-US$95m

보상 대 시장: Weihui 의 총 보상 ($USD 2.48M )은 Hong Kong 시장( $USD 481.50K ).

보상과 수익: Weihui 의 보상을 회사 성과와 비교하기에는 데이터가 부족합니다.

CEO

Weihui Shao (44 yo)

3.3yrs

테뉴어

US$2,477,000

보상

Ms. Weihui Shao is Chief Operating Officer of Genscript Biotech Corporation from July 08, 2021 and serves as its Rotating Chief Executive Officer since January 01, 2023. She joined the Genscript Biotech Co...

리더십 팀

이름	위치	테뉴어	보상	소유권
Jiange Meng	Executive Chairman	9.3yrs	US$495.00k	0.013% HK$ 3.0m
Weihui Shao	CEO & COO	3.3yrs	US$2.48m	0.034% HK$ 7.7m
Ye Wang	Co-Founder	22.8yrs	US$659.00k	0.036% HK$ 8.3m
Luquan Wang	Co-Founder & Non-Executive Director	no data	데이터 없음	0.030% HK$ 6.8m
Fangliang Zhang	Co-Founder & Executive Director	1.9yrs	US$531.00k	데이터 없음
Li Zhu	Chief Strategy Officer & Executive Director	4yrs	US$320.00k	0.054% HK$ 12.2m
Shiniu Wei	Chief Financial Officer	3.9yrs	데이터 없음	데이터 없음
Aylin Bilgin	Chief Marketing Officer for GenScript Life Science Group	no data	데이터 없음	데이터 없음

3.6yrs

평균 재임 기간

56yo

평균 연령

경험이 풍부한 관리: 1548 의 관리팀은 경험 ( 3.6 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Jiange Meng	Executive Chairman	9.3yrs	US$495.00k	0.013% HK$ 3.0m
Ye Wang	Co-Founder	9.5yrs	US$659.00k	0.036% HK$ 8.3m
Luquan Wang	Co-Founder & Non-Executive Director	9.5yrs	데이터 없음	0.030% HK$ 6.8m
Fangliang Zhang	Co-Founder & Executive Director	2.5yrs	US$531.00k	데이터 없음
Li Zhu	Chief Strategy Officer & Executive Director	4yrs	US$320.00k	0.054% HK$ 12.2m
Carl June	Member of Advisory Board	less than a year	데이터 없음	데이터 없음
George Church	Member of Advisory Board	5.2yrs	데이터 없음	데이터 없음
Alphonse Galdes	Independent Non-Executive Director	less than a year	데이터 없음	데이터 없음
David Liu	Member of Scientific Advisory Board	less than a year	데이터 없음	데이터 없음
Yiu Leung Cheung	Independent Non-Executive Director	less than a year	데이터 없음	데이터 없음
Chenyang Shi	Independent Non-Executive Director	less than a year	데이터 없음	데이터 없음
Ethan Pan	Independent Non-Executive Director	less than a year	데이터 없음	데이터 없음

1.7yrs

평균 재임 기간

61.5yo

평균 연령

경험이 풍부한 이사회: 1548 의 이사회는 경험(평균 재직 기간 1.7 년)으로 간주되지 않으므로 새 이사회가 필요합니다.

Genscript Biotech 관리

관리 기준 확인 1/4

주요 정보

최근 관리 업데이트

Genscript Biotech Corporation Appoints Aylin Kosova Bilgin Has Joined as the First-Ever Chief Marketing Officer for GenScript Life Science Group

Board Member recently sold HK$901k worth of stock

Genscript Biotech Corporation Announces Board Appointments

Genscript Biotech Corporation Announces Board Resignations and Changes in Composition of Board Committees

Insider recently sold HK$1.0m worth of stock

Genscript Biotech Corporation Announces Directorate Appointments and Change in Composition of Board Committee

Recent updates

Genscript Biotech Corporation Appoints Aylin Kosova Bilgin Has Joined as the First-Ever Chief Marketing Officer for GenScript Life Science Group

Board Member recently sold HK$901k worth of stock

Now 21% overvalued after recent price rise

Genscript Biotech Corporation Announces Late-Breaking Long-Term Overall Survival Data from Cartitude-4 Study in Multiple Myeloma

Genscript Biotech Corporation Announces Board Appointments

First half 2024 earnings released: US$0.083 loss per share (vs US$0.044 loss in 1H 2023)

First half 2024 earnings released: US$0.083 loss per share (vs US$0.044 loss in 1H 2023)

Genscript Biotech Corporation to Report First Half, 2024 Results on Aug 09, 2024

New minor risk - Share price stability

Genscript Biotech Corporation Announces Board Resignations and Changes in Composition of Board Committees

GenScript Biotech Corporation Launches FLASH Gene Service: The Most Affordable Gene Synthesis Solution on the Market

Now 22% undervalued after recent price drop

GenScript Biotech Corporation Announces Self-Amplifying RNA Synthesis Service for Advanced Therapeutic Applications

Full year 2023 earnings released: US$0.045 loss per share (vs US$0.11 loss in FY 2022)

Now 25% undervalued after recent price drop

Insider recently sold HK$1.0m worth of stock

Genscript Biotech Corporation Announces Directorate Appointments and Change in Composition of Board Committee

Board Member recently sold HK$455k worth of stock

Genscript Biotech Corporation, Annual General Meeting, May 17, 2024

Full year 2023 earnings released: US$0.045 loss per share (vs US$0.11 loss in FY 2022)

Genscript Announces Appointment of Dr. David R. Liu to the Scientific Advisory Board

Genscript Biotech Corporation to Report Fiscal Year 2023 Final Results on Mar 09, 2024

New minor risk - Profitability

Executive Chairman recently sold HK$610k worth of stock

GenScript Biotech Corporation Expands its IVT mRNA Synthesis Portfolio with Addition of Customized Circular RNA and Lipid Nanoparticles Formulation Services

First half 2023 earnings released: US$0.044 loss per share (vs US$0.063 loss in 1H 2022)

Genscript Biotech Corporation to Report First Half, 2023 Results on Aug 19, 2023

Insider recently sold HK$1.4m worth of stock

Full year 2022 earnings released: US$0.11 loss per share (vs US$0.17 loss in FY 2021)

Now 24% undervalued

Now 20% undervalued

Genscript Biotech Corporation Announces Chief Executive Officer Changes

Genscript Biotech Corporation Announces Redesignation of Dr. Zhang Fangliang from A Non-Executive Director to an Executive Director with Effect from December 17, 2022

Less than half of directors are independent

First half 2022 earnings released: US$0.063 loss per share (vs US$0.046 loss in 1H 2021)

Genscript Biotech Corporation to Report First Half, 2022 Results on Aug 31, 2022

Genscript Biotech Corporation Provides Earnings Guidance for the Six Months Ended June 30, 2022

Genscript Biotech Corporation Announces Board Changes

Genscript Biotech Corporation Announces Board Changes

Full year 2021 earnings released: US$0.17 loss per share (vs US$0.11 loss in FY 2020)

Less than half of directors are independent

Genscript Biotech Corporation, Annual General Meeting, May 27, 2022

Genscript Biotech Corporation Provides Earnings Guidance for the Year Ended 31 December 2021

Board Member recently sold HK$2.1m worth of stock

First half 2021 earnings released: US$0.046 loss per share (vs US$0.06 loss in 1H 2020)

Key Executive recently sold HK$9.1m worth of stock

Duke-NUS Medical School and GenScript Biotech Corporation Announce Notice of Allowance for U.S. Patent Application for SARS-CoV-2 Surrogate Virus Neutralization Test

Hillhouse Capital Management, Ltd. completed the acquisition of 2.99% stake in Genscript Biotech Corporation (SEHK:1548) from GenScript Corporation.

Full year 2020 earnings released: US$0.11 loss per share (vs US$0.052 loss in FY 2019)

Full year 2020 earnings released

Genscript Biotech Corporation to Report Fiscal Year 2020 Results on Mar 26, 2021

New 90-day high: HK$14.66

Genscript Probio and Neoletix Announce Successful Completion of 200-Liter Gmp Production Runs of Recombinant Coagulation Fviii Based on A Novel Production Technology

New 90-day low: HK$10.18

New 90-day low: HK$10.36

Genscript Biotech Corporation Announces Board and Director Changes

New 90-day low: HK$11.38

Co-Founder recently bought HK$3.7m worth of stock

First half earnings released

New 90-day low: HK$11.48

First half earnings released

New 90-day low - HK$14.96

Genscript Biotech Corporation to Report Q2, 2020 Results on Aug 29, 2020

Genscript Biotech Corporation Announces Management Changes Effective 2 August 2020

CEO 보상 분석

CEO

테뉴어

보상

리더십 팀